The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FPA144-001: A first in human study of FPA 144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody in patients with advanced solid tumors.
 
Johanna C. Bendell
No Relationships to Disclose
 
Seema Rogers
Employment - Exelixis (I); Five Prime Therapeutics; InterMune (I); Relypsa (I)
Stock and Other Ownership Interests - Exelixis (I); Five Prime Therapeutics
Consulting or Advisory Role - Exelixis (I); Exelixis (I); InterMune (I); Relypsa (I)
Travel, Accommodations, Expenses - Exelixis (I); Five Prime Therapeutics; InterMune (I); Relypsa (I)
 
Hong Xiang
Employment - Five Prime Therapeutics; Genentech/Roche
Stock and Other Ownership Interests - Five Prime Therapeutics; Genentech/Roche
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics; Genentech/Roche
Travel, Accommodations, Expenses - Five Prime Therapeutics; Genentech/Roche
 
Kristen L. Pierce
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
Patents, Royalties, Other Intellectual Property - Five Prime Therapeutics
 
Kartik Krishnan
Employment - Biomarin (I); Five Prime Therapeutics
Stock and Other Ownership Interests - Biomarin; Biomarin (I); Five Prime Therapeutics; Roche/Genentech
 
Robert S. Sikorski
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics
Patents, Royalties, Other Intellectual Property - Johns Hopkins Hospital
Other Relationship - MedImmune
 
Julie Hambleton
Employment - Five Prime Therapeutics
Stock and Other Ownership Interests - Five Prime Therapeutics; Five Prime Therapeutics (I)
 
Drew W. Rasco
Research Funding - Asana Biosciences; Bayer; Celgene; Eisai; Five Prime Therapeutics; Millennium; Pharmacyclics; Rexahn Pharmaceuticals; Santa Maria Biotherapeutics; Teva
Travel, Accommodations, Expenses - Millennium